Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice TargetHot
Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.
Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.